Market Research Logo

Chugai Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016

Chugai Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Chugai Pharmaceutical Co., Ltd. - Product Pipeline Review, 2016’, provides an overview of the Chugai Pharmaceutical Co., Ltd.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Chugai Pharmaceutical Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Chugai Pharmaceutical Co., Ltd.
  • The report provides overview of Chugai Pharmaceutical Co., Ltd. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Chugai Pharmaceutical Co., Ltd.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Chugai Pharmaceutical Co., Ltd.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
  • Evaluate Chugai Pharmaceutical Co., Ltd.’s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Chugai Pharmaceutical Co., Ltd.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Chugai Pharmaceutical Co., Ltd.’s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Chugai Pharmaceutical Co., Ltd. Snapshot
Chugai Pharmaceutical Co., Ltd. Overview
Key Information
Key Facts
Chugai Pharmaceutical Co., Ltd. - Research and Development Overview
Key Therapeutic Areas
Chugai Pharmaceutical Co., Ltd. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Pipeline Products - Out-Licensed Products
Out-Licensed Products/Combination Treatment Modalities
Chugai Pharmaceutical Co., Ltd. - Pipeline Products Glance
Chugai Pharmaceutical Co., Ltd. - Late Stage Pipeline Products
Phase III Products/Combination Treatment Modalities
Chugai Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Chugai Pharmaceutical Co., Ltd. - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Chugai Pharmaceutical Co., Ltd. - Drug Profiles
atezolizumab
Product Description
Mechanism of Action
R&D Progress
bevacizumab
Product Description
Mechanism of Action
R&D Progress
eldecalcitol
Product Description
Mechanism of Action
R&D Progress
gantenerumab
Product Description
Mechanism of Action
R&D Progress
lebrikizumab
Product Description
Mechanism of Action
R&D Progress
obinutuzumab
Product Description
Mechanism of Action
R&D Progress
SA-237
Product Description
Mechanism of Action
R&D Progress
tocilizumab
Product Description
Mechanism of Action
R&D Progress
codrituzumab
Product Description
Mechanism of Action
R&D Progress
nemolizumab
Product Description
Mechanism of Action
R&D Progress
basmisanil
Product Description
Mechanism of Action
R&D Progress
EOS-789
Product Description
Mechanism of Action
R&D Progress
PCO-371
Product Description
Mechanism of Action
R&D Progress
polatuzumab vedotin
Product Description
Mechanism of Action
R&D Progress
RG-7304
Product Description
Mechanism of Action
R&D Progress
taselisib
Product Description
Mechanism of Action
R&D Progress
CH-5036249
Product Description
Mechanism of Action
R&D Progress
CH-5164840
Product Description
Mechanism of Action
R&D Progress
CH-5449302
Product Description
Mechanism of Action
R&D Progress
CH-5451098
Product Description
Mechanism of Action
R&D Progress
CVE-199
Product Description
Mechanism of Action
R&D Progress
ERY-974
Product Description
Mechanism of Action
R&D Progress
maxacalcitol
Product Description
Mechanism of Action
R&D Progress
NA-255
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein to Agonize PTHR1 for Hypoparathyroidism
Product Description
Mechanism of Action
R&D Progress
gMSC-1
Product Description
Mechanism of Action
R&D Progress
Chugai Pharmaceutical Co., Ltd. - Pipeline Analysis
Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Target
Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration
Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type
Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action
Chugai Pharmaceutical Co., Ltd. - Recent Pipeline Updates
Chugai Pharmaceutical Co., Ltd. - Dormant Projects
Chugai Pharmaceutical Co., Ltd. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
nitazoxanide
basimglurant
bevacizumab
hyaluronate sodium
NA-808
onartuzumab
orlistat
PA-799
parsatuzumab
pictilisib
RG-7167
sembragiline
tocilizumab
trastuzumab emtansine
Chugai Pharmaceutical Co., Ltd. - Company Statement
Chugai Pharmaceutical Co., Ltd. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Chugai Pharmaceutical Co., Ltd., Key Information
Chugai Pharmaceutical Co., Ltd., Key Facts
Chugai Pharmaceutical Co., Ltd. - Pipeline by Indication, 2016
Chugai Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2016
Chugai Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2016
Chugai Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2016
Chugai Pharmaceutical Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2016
Chugai Pharmaceutical Co., Ltd. - Out-Licensed Products in Pipeline, 2016
Chugai Pharmaceutical Co., Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2016
Chugai Pharmaceutical Co., Ltd. - Phase III, 2016
Chugai Pharmaceutical Co., Ltd. - Phase II, 2016
Chugai Pharmaceutical Co., Ltd. - Phase I, 2016
Chugai Pharmaceutical Co., Ltd. - Preclinical, 2016
Chugai Pharmaceutical Co., Ltd. - Discovery, 2016
Chugai Pharmaceutical Co., Ltd. - Pipeline by Target, 2016
Chugai Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2016
Chugai Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2016
Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2016
Chugai Pharmaceutical Co., Ltd. - Recent Pipeline Updates, 2016
Chugai Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2016
Chugai Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2016
Chugai Pharmaceutical Co., Ltd., Other Locations
Chugai Pharmaceutical Co., Ltd., Subsidiaries
ist of Figures
Chugai Pharmaceutical Co., Ltd. - Pipeline by Top 10 Indication, 2016
Chugai Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2016
Chugai Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2016
Chugai Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2016
Chugai Pharmaceutical Co., Ltd. - Out-Licensed Products in Pipeline, 2016
Chugai Pharmaceutical Co., Ltd. - Pipeline by Top 10 Target, 2016
Chugai Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2016
Chugai Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2016
Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report